.png){kind=icon}
Return
CAR-X cell engineering
.png){kind=icon}
PRE
AI
DOI：10.1038/s44222-026-00430-w.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of haematological malignancies and continues to transform the treatment of various other diseases. Nonetheless, current CAR-T cell therapy has limitations that hinder its therapeutic efficacy for expanded applications, some of which might be attributed to intrinsic T cell features. Using immune cells beyond conventional T cells has therefore emerged as a promising strategy to compensate for such limitations. In this Review, we discuss different CAR-engineered immune cells for therapeutic applications by highlighting how unique immune attributes, along with cell-specific manufacturing strategies and CAR designs, address challenges faced by conventional CAR-T cell therapy.
Keywords:
REGULATORY T-CELLS
NATURAL-KILLER-CELLS
TUMOR-ASSOCIATED MACROPHAGES
NK-92 CELLS
NKT CELLS
CD28 COSTIMULATION
EPIGENETIC CHANGES
ANTITUMOR-ACTIVITY
CHIMERIC-RECEPTOR
FOXP3 EXPRESSION
Journal
N
IF:
37.6
Papers:
92
Citations:
0
Organization
Cited Papers
ShareSaveShareSaveOX40 Ligand Contributes to Human Lupus Pathogenesis by Promoting T Follicular Helper Response.png)
IMMUNITY
OAAI
IMMUNITYIF26.3
OAAIShareSaveRegulatory T Cells Control Antigen-Specific Expansion of Tfh Cell Number and Humoral Immune Responses via the Coreceptor CTLA-4IMMUNITYOAAI
IMMUNITYIF26.3
OAAIShareSaveShareSaveEngineering macrophages to eat cancer: from marker of self CD47 and phagocytosis to differentiationOAAI
OAAIShareSaveAllogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosisCell
CellIF0
PREAI
ShareSave
View more